Introduction Bringing a new therapy from concept to market is a long, complex, and resource-intensive process. Timelines typically extend 8–12 years and costs can exceed $2 billion [1]. Despite this investment, only about 10% of drugs entering clinical trials ultimately receive approval [2]. These inefficiencies stem from high attrition rates, translation gaps between preclinical and […]
Over the past several decades, drug development has expanded from traditional small-molecule chemicals to a diverse array of therapeutic modalities. These include biologics such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), nucleic acid-based therapies (siRNA, antisense oligonucleotides, mRNA vaccines), gene and cell therapies (including gene editing), and radiopharmaceuticals. In this deep dive, we explore the
Evolution of Therapeutic Modalities: FDA Approvals and Innovation Landscape Read More »
In today’s complex drug development landscape, PBPK and QSP modeling are key tools that help bridge data, de-risk decisions, and support regulatory interactions. PBPK Modeling Physiologically Based Pharmacokinetic (PBPK) models describe drug disposition in the body based on organ-specific physiology and biochemistry. They are commonly used for: PBPK is especially useful in early development and
PBPK and QSP: Two Powerful Tools for Drug Development — When and Why to Use Each Read More »
Introduction Oncology drug development has traditionally shunned healthy volunteer (HV) participation due to the high toxicity of classic chemotherapies [1]. Cytotoxic agents non-selectively kill rapidly dividing cells, causing severe side effects that would be unethical in individuals without cancer. However, the therapeutic landscape is changing. Over the past two decades, targeted therapies—drugs aimed at specific
Even if you never build a PBPK model in-house, an early decision framework—knowing when PBPK can replace, complement, or simply de-risk clinical studies—cuts duplicated work and answers “what-if” regulatory questions before they become clock-stopping RFIs. Why deciding early—not necessarily modeling early—saves studies, budget, and review stress Small molecule therapies—and, occasionally, intravenous antibody–drug conjugates (ADCs) carrying
Physiologically-Based PK (PBPK) Modeling: Your Fast-Pass for DDI & Food-Effect Strategy Read More »
Executive snapshot Filing separate first-in-human (FIH) dossiers for the United States and Europe can drag an early-stage program six-plus months behind plan. A harmonised approach—one Common Technical Document (CTD) “master” that slots into both the FDA Investigational New Drug (IND) sequence and the EU Clinical Trials Regulation (CTR) portal (CTIS)—cuts review-cycle queries by ~35 %,
IND vs IMPD: Building One Data Package That Satisfies Both FDA & EU Regulators Read More »
Emerging biotech companies—and small to midsize pharma firms—face extraordinary constraints. Timelines are compressed, funding is finite, and regulatory expectations continue to evolve. These pressures make it essential to have a strategic development plan that integrates scientific rigor, operational efficiency, and regulatory foresight from the earliest stages. Biotech innovation is advancing at remarkable speed—but development timelines,
Why Clinical Pharmacology and Regulatory Strategy Are Critical for Emerging Biotechs Read More »
